Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer

Inhibitor of apoptosis proteins (IAPs) regulate apoptosis and modulate NF‐κB signaling thereby driving expression of genes involved in immune/inflammatory responses. The orally available IAP antagonist Debio 1143 has potential to enhance tumor response to chemoradiotherapy and/or immunotherapy. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez‐Roca, Carlos, Even, Caroline, Le Tourneau, Christophe, Basté, Neus, Delord, Jean‐Pierre, Sarini, Jerome, Vergez, Sebastien, Temam, Stephane, Hoffmann, Caroline, Rochaix, Philippe, Borcoman, Edith, Gavillet, Bruno, Rouits, Elisabeth, Ménétrey, Annick, Brichory, Franck, Purcea, Daniela, Vuagniaux, Gregoire, Zanna, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742634/
https://www.ncbi.nlm.nih.gov/pubmed/33742767
http://dx.doi.org/10.1111/cts.13002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742634/
https://www.ncbi.nlm.nih.gov/pubmed/33742767
http://dx.doi.org/10.1111/cts.13002

Ejemplares similares